眾生藥業(002317.SZ)：眾生睿創擬以現金增資方式引入投資者
格隆匯 12 月 15日丨眾生藥業(002317.SZ)公佈，為了補充創新藥研發項目的資金，推進公司發展和創新藥研發項目進程，公司控股子公司廣東眾生睿創生物科技有限公司(“眾生睿創”)擬以現金增資方式引入投資者，新增註冊資本人民幣15,277,717元，由此次新引入投資者湖州景鑫股權投資合夥企業(有限合夥)(“湖州景鑫”)、江蘇紫金弘雲健康產業投資合夥企業(有限合夥)(“紫金弘雲”)、LBC Sunshine Healthcare Fund II L.P. (“LBC”)、杭州向康倚鋒創業投資合夥企業(有限合夥)(“向康倚鋒”)、交銀科創股權投資基金(上海)合夥企業(有限合夥)(“交銀科創”)、青島信鴻創業投資合夥企業(有限合夥)(“青島信鴻”)及眾生睿創現股東BioTrack Capital Fund I, LP (“BioTrack”)、公司合計以人民幣2.3億元和美元800萬元全額認繳此次新增註冊資本，超出部分計入眾生睿創的資本公積。
眾生睿創現有股東：廣東博觀元創生物科技研究中心(有限合夥)(“元創生物”)、Snow Owl, LLC (“Snow Owl”)、Southern Orchard Limited (“Southern Orchard”)、東莞睿創醫藥研究開發中心(有限合夥)(“睿創醫藥”)以及周雪莉放棄此次對眾生睿創增資的優先認購權。
公司此次以自有資金出資人民幣3000萬元，認繳本次新增註冊資本1,623,626元，超出部分計入眾生睿創的資本公積。此次控股子公司眾生睿創增資完成後，其註冊資本由人民幣135,302,198元增加至人民幣150,579,915元，公司持股比例由68.37%變為62.51%，眾生睿創仍為公司控股子公司。董事會同意授權公司董事長根據具體情況實施相關事宜並簽署有關協議及文件。
2020年12月15日，眾生睿創、公司、睿創醫藥、周雪莉、Snow Owl、Southern Orchard、BioTrack、元創生物及眾生睿創新投資人湖州景鑫、紫金弘雲、LBC、向康倚鋒、交銀科創、青島信鴻簽署了相關文件。
圍繞公司的“十三五”戰略規劃，推進公司研發戰略實施，保持公司對控股子公司的控股地位以及基於眾生睿創未來獨立上市可能性的考慮，實施眾生睿創B輪融資增資擴股暨公司現金增資事項。
眾生睿創以現金增資方式引進戰略投資者，實施B輪融資，拓寬資本市場的融資渠道，提升眾生睿創的融資能力，帶來資金支持，共擔研發投資風險，共同推進創新藥研發項目。
眾生睿創B輪融資的實現，為創新藥未來研發資金投入創造必要條件，也為日後的資本引進奠定了良好的基礎，加快創新藥項目開發和藥品上市的進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
